



## *Manufacturer's Information*

# **Test No. 22-5802: DNA-Semen**

---

Each sample pack consisted of two known bloodstains on FTA cards (Items 1 & 2), and two questioned stains on clean, colored fabric (Item 3 & 4). Participants were requested to analyze these items using their existing protocols.

**SAMPLE PREPARATION:** The stains in Items 1, 2, and 3 were prepared from human whole blood which was either drawn into citric acid preservative bags or EDTA tubes. The stain in Item 4 was a mixture prepared from human whole blood and semen. The semen sample was first thawed and mixed 1:1 with TAE buffer, then mixed 1:1 with the blood. Item 1 (75  $\mu$ l) was prepared using blood collected from a female donor. Item 2 (75  $\mu$ l) was created using blood collected from a male donor. Item 3 (50  $\mu$ l) was created using blood collected from a male donor, but one different than that of Item 2. Item 4 (50  $\mu$ l) was created using a mixture of blood from the female donor used in Item 1 and semen from the male donor used in Item 2. Stains from different sources were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on February 28, 2022 following completion of verification stage.

**SAMPLE SET ASSEMBLY:** For each sample set, all four Items (1-4) were packed into separate envelopes and then placed together in a pre-labeled sample pack envelope and sealed. The sealed sample pack envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

**VERIFICATION:** Laboratories that conducted predistribution analysis of the samples reported consistent allelic results and confirmed the manufacturer's expected associations.

**Manufacturer's Information, continued**  
**Test No. 22-5802: DNA-Semen**

<b>Amelogenin and STR Results</b>						
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>						
<b>Item</b>	<b>D1S1656</b>	<b>D2S1338</b>	<b>D2S441</b>	<b>D3S1358</b>	<b>D5S818</b>	<b>D6S1043</b>
	<b>D7S820</b>	<b>D8S1179</b>	<b>D10S1248</b>	<b>D12S391</b>	<b>D13S317</b>	<b>D16S539</b>
	<b>D18S51</b>	<b>D19S433</b>	<b>D21S11</b>	<b>D22S1045</b>	<b>Amelogenin</b>	<b>CSF1PO</b>
	<b>FGA</b>	<b>Penta D</b>	<b>Penta E</b>	<b>SE33</b>	<b>TH01</b>	<b>TPOX</b>
	<b>vWA</b>	<b>DYS391</b>	<b>DYS570</b>	<b>DYS576</b>	<b>Y Indel</b>	
1	16,18.3	21,26	11,12	15,17	11,12	*
	10,10	10,14	14,16	17,21	13,13	9,14
	13,16	13,15	31,32.2	15,15	X,X	10,11
	20,21	9,9	5,10	19,24.2	6,7	8,11
	14,17	NM	NM	NM	NM	
2	14,16.3	17,24	11,14	16,18	11,12	*
	9,11	13,13	13,14	18,21	11,14	11,12
	16,17	15,16.2	30,30	15,16	X,Y	11,12
	20,22	12,14	10,14	29.2,29.2	9,9.3	8,8
	14,17	11	17	19	2	
3	15,15.3	20,25	11.3,14	14,17	12,13	*
	7,11	13,13	14,14	18,19	9,9	10,12
	13,14	13,16	31.2,31.2	15,17	X,Y	10,11
	20,23	9,13	12,13	16,17	7,9.3	8,11
	17,17	10	19	20	2	
4-Blood	16,18.3	21,26	11,12	15,17	11,12	*
	10,10	10,14	14,16	17,21	13,13	9,14
	13,16	13,15	31,32.2	15,15	X,X	10,11
	20,21	9,9	5,10	19,24.2	6,7	8,11
	14,17	NM	NM	NM	NM	
4-Semen	14,16.3	17,24	11,14	16,18	11,12	*
	9,11	13,13	13,14	18,21	11,14	11,12
	16,17	15,16.2	30,30	15,16	X,Y	11,12
	20,22	12,14	10,14	29.2,29.2	9,9.3	8,8
	14,17	11	17	19	2	

<b>YSTR Results</b>									
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>									
<b>Item</b>	<b>DYF387S1</b>	<b>DYS19</b>	<b>DYS385</b>	<b>DYS389-I</b>	<b>DYS389-II</b>	<b>DYS390</b>	<b>DYS391</b>	<b>DYS392</b>	<b>DYS393</b>
	<b>DYS437</b>	<b>DYS438</b>	<b>DYS439</b>	<b>DYS448</b>	<b>DYS449</b>	<b>DYS456</b>	<b>DYS458</b>	<b>DYS460</b>	<b>DYS481</b>
	<b>DYS518</b>	<b>DYS533</b>	<b>DYS549</b>	<b>DYS570</b>	<b>DYS576</b>	<b>DYS627</b>	<b>DYS635</b>	<b>DYS643</b>	<b>YGATAH4</b>
2	35,36	14	11,14	13	29	24	11	14	12
	15	12	12	19	30	15	17	11	22
	38	12	12	17	19	23	23	10	13
3	37,40	14	16,16	13	29	25	10	13	12
	14	11	10	20	28	17	16.2	11	26
	41	12	12	19	20	21	21	9	10
4-Semen	35,36	14	11,14	13	29	24	11	14	12
	15	12	12	19	30	15	17	11	22
	38	12	12	17	19	23	23	10	13

\* Results were not received by a minimum of 10 participants for the loci indicated.

NM - Non-Male profile, YSTR results not expected.

*The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.*